Tarsus Pharmaceuticals, Inc.

TARS

$78.21

Name : Tarsus Pharmaceuticals, Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $3,319,944,448.00

EPSttm : -1.99

Tarsus Pharmaceuticals, Inc.

$78.21

0.17%

$0.13

Float Short %

17.39

Margin Of Safety %

Put/Call OI Ratio

0.41

EPS Next Q Diff

0.23

EPS Last/This Y

1.66

EPS This/Next Y

2.75

Price

78.25

Target Price

87.5

Analyst Recom

1.3

Performance Q

12.13

Relative Volume

0.8

Beta

0.58

Ticker: TARS

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-10	TARS	81.19	0.03	0.00	2582
2025-12-11	TARS	81.74	0.03	0.00	2590
2025-12-12	TARS	81.35	0.03	0.00	2588
2025-12-15	TARS	80.49	0.03	0.00	2594
2025-12-16	TARS	78.29	0.03	0.04	2596
2025-12-17	TARS	77.81	0.04	0.65	2615
2025-12-18	TARS	77.45	0.33	0.02	5994
2025-12-19	TARS	81.34	0.34	0.02	5928
2025-12-22	TARS	81.44	0.37	0.04	5330
2025-12-23	TARS	82.25	0.37	0.04	5285
2025-12-26	TARS	81.73	0.39	1.08	5317
2025-12-29	TARS	82.02	0.39	3.00	5329
2025-12-30	TARS	82.36	0.40	0.38	5343
2025-12-31	TARS	81.84	0.40	0.43	5338
2026-01-02	TARS	80.7	0.40	0.42	5346
2026-01-05	TARS	79.78	0.40	0.44	5382
2026-01-06	TARS	79.16	0.41	0.33	5393
2026-01-07	TARS	77.72	0.41	1.44	5391
2026-01-08	TARS	78.3	0.41	0.29	5404
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-10	TARS	81.24	99.4	-	-1.41
2025-12-11	TARS	81.76	99.4	-	-1.41
2025-12-12	TARS	81.39	99.4	-	-1.41
2025-12-15	TARS	80.48	99.4	-	-1.41
2025-12-16	TARS	80.48	99.4	-	-1.41
2025-12-17	TARS	77.80	99.4	-	-1.41
2025-12-18	TARS	77.46	99.4	-	-1.41
2025-12-19	TARS	81.39	99.4	-	-1.41
2025-12-22	TARS	81.60	99.4	-	-1.41
2025-12-23	TARS	82.18	99.4	-	-1.41
2025-12-26	TARS	81.75	99.4	-	-1.41
2025-12-29	TARS	81.97	99.4	-	-1.41
2025-12-30	TARS	82.35	99.4	-	-1.41
2025-12-31	TARS	81.96	99.4	-	-1.41
2026-01-02	TARS	80.60	99.4	-	-1.41
2026-01-05	TARS	79.81	99.4	-	-1.41
2026-01-06	TARS	79.80	99.4	-	-1.41
2026-01-07	TARS	78.03	99.4	-	-1.41
2026-01-08	TARS	78.25	99.4	-	-1.41
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-10	TARS	-2.09	-4.23	18.20
2025-12-11	TARS	-2.09	-4.23	18.20
2025-12-12	TARS	-1.58	-4.23	18.20
2025-12-15	TARS	-1.58	-4.23	18.19
2025-12-16	TARS	-1.59	-4.23	18.19
2025-12-17	TARS	-2.28	-4.23	18.19
2025-12-18	TARS	-2.10	-4.23	18.19
2025-12-19	TARS	-2.10	-4.23	18.19
2025-12-22	TARS	-2.10	-4.24	18.18
2025-12-23	TARS	-2.12	-4.24	18.18
2025-12-26	TARS	-2.12	-4.24	17.39
2025-12-29	TARS	-2.12	-4.19	17.39
2025-12-30	TARS	-2.12	-4.19	17.39
2025-12-31	TARS	-2.29	-4.19	17.39
2026-01-02	TARS	-2.29	-4.19	17.39
2026-01-05	TARS	-2.29	-3.99	17.39
2026-01-06	TARS	-2.75	-3.99	17.39
2026-01-07	TARS	-2.75	-3.99	17.39
2026-01-08	TARS	-2.75	-3.99	17.39
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-0.3

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

-0.07

Insider Transactions

-2.75

Institutional Transactions

-3.99

Beta

0.58

Average Sales Estimate Current Quarter

143

Average Sales Estimate Next Quarter

148

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

8.2

Max Drawdown 5-Year %

-76.6

Target Price

87.5

P/E

Forward P/E

44.74

PEG

P/S

9.07

P/B

9.91

P/Free Cash Flow

EPS

-2.01

Average EPS Est. Cur. Y

-1.41

EPS Next Y. (Est.)

1.33

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-22.17

Relative Volume

0.8

Return on Equity vs Sector %

-51.5

Return on Equity vs Industry %

-36.1

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.01

EBIT Estimation

Tarsus Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 323

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community malaria reduction. In addition, the company develops lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

stock quote shares TARS – Tarsus Pharmaceuticals Inc Stock Price stock today

news today TARS – Tarsus Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch TARS – Tarsus Pharmaceuticals Inc yahoo finance google finance

stock history TARS – Tarsus Pharmaceuticals Inc invest stock market

stock prices TARS premarket after hours

ticker TARS fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: TARS

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y